Prevalence of erectile dysfunction as long-COVID symptom in hospitalized Japanese patients

Abstract Coronavirus disease-2019 (COVID-19) is associated with a wide range of post-acute sequelae. The prevalence of erectile dysfunction (ED) that developed after COVID-19 and the associated underlying factors were analyzed based on a questionnaire survey, COVID-19 Recovery Study II in Japan. A c...

Full description

Saved in:
Bibliographic Details
Main Authors: Hideaki Kato, Nao Ichihara, Hiroki Saito, Shigeki Fujitani, Kohei Ota, Yuji Takahashi, Toshiyuki Harada, Takeshi Hattori, Mitsuru Komeya, Mariko Hosozawa, Yoko Muto, Miyuki Hori, Arisa Iba, Hiroyasu Iso, The COVID-19 Recovery Study II Group
Format: Article
Language:English
Published: Nature Portfolio 2025-02-01
Series:Scientific Reports
Subjects:
Online Access:https://doi.org/10.1038/s41598-025-88904-6
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849723103404359680
author Hideaki Kato
Nao Ichihara
Hiroki Saito
Shigeki Fujitani
Kohei Ota
Yuji Takahashi
Toshiyuki Harada
Takeshi Hattori
Mitsuru Komeya
Mariko Hosozawa
Yoko Muto
Miyuki Hori
Arisa Iba
Hiroyasu Iso
Hiroyasu Iso
The COVID-19 Recovery Study II Group
author_facet Hideaki Kato
Nao Ichihara
Hiroki Saito
Shigeki Fujitani
Kohei Ota
Yuji Takahashi
Toshiyuki Harada
Takeshi Hattori
Mitsuru Komeya
Mariko Hosozawa
Yoko Muto
Miyuki Hori
Arisa Iba
Hiroyasu Iso
Hiroyasu Iso
The COVID-19 Recovery Study II Group
author_sort Hideaki Kato
collection DOAJ
description Abstract Coronavirus disease-2019 (COVID-19) is associated with a wide range of post-acute sequelae. The prevalence of erectile dysfunction (ED) that developed after COVID-19 and the associated underlying factors were analyzed based on a questionnaire survey, COVID-19 Recovery Study II in Japan. A case–control study was conducted with those with or without ED one and two years hospitalized with COVID-19 between March and September 2021. Six hundred and nine Japanese men, with a median age of 48 years, were analyzed. During the study period, 116 subjects (19.0%) had erectile dysfunction. The patients with ED responded with less subjective awareness of recovery and high breathless and fatigue scores compared to those without ED. The patients with ED also showed higher Hospital Anxiety and Depression Scale-D (depression) and the EuroQol 5-dimensions 5-level scores for pain/discomfort and anxiety/depression scores compared before COVID-19 infection. Sleep disturbance was suggested to be associated with erectile dysfunction using an exploratory clustering analysis in the one-year survey. There were no associations of COVID-19 severity, reinfection, vaccination frequency, antiviral treatment for COVID-19 with the presence of erectile dysfunction. It was considered that mental support for the subject with erectile dysfunction as a long-COVID symptom is warranted.
format Article
id doaj-art-4391dc11bf4f46fa89cfe1b4ffca2449
institution DOAJ
issn 2045-2322
language English
publishDate 2025-02-01
publisher Nature Portfolio
record_format Article
series Scientific Reports
spelling doaj-art-4391dc11bf4f46fa89cfe1b4ffca24492025-08-20T03:11:07ZengNature PortfolioScientific Reports2045-23222025-02-011511710.1038/s41598-025-88904-6Prevalence of erectile dysfunction as long-COVID symptom in hospitalized Japanese patientsHideaki Kato0Nao Ichihara1Hiroki Saito2Shigeki Fujitani3Kohei Ota4Yuji Takahashi5Toshiyuki Harada6Takeshi Hattori7Mitsuru Komeya8Mariko Hosozawa9Yoko Muto10Miyuki Hori11Arisa Iba12Hiroyasu Iso13Hiroyasu Iso14The COVID-19 Recovery Study II GroupInfection Prevention and Control Department, Yokohama City University HospitalDepartment of Medical Innovation, University of Osaka Graduate School of MedicineDepartment of Emergency and Critical Care Medicine, St. Marianna University School of MedicineDepartment of Emergency and Critical Care Medicine, St. Marianna University School of MedicineDepartment of Emergency and Critical Care Medicine, Graduate School of Biomedical & Health Sciences, Hiroshima UniversityDepartment of Emergency and Critical Care Medicine, Hitachi General HospitalCenter for Respiratory Diseases, Japan Community Healthcare Organization, Hokkaido HospitalDepartment of Respiratory Medicine, National Hospital Organization Hokkaido Medical CenterDepartment of Urology, Yokohama City University HospitalInstitute for Global Health Policy Research, Bureau of International Health Cooperation, National Center for Global Health and MedicineInstitute for Global Health Policy Research, Bureau of International Health Cooperation, National Center for Global Health and MedicineInstitute for Global Health Policy Research, Bureau of International Health Cooperation, National Center for Global Health and MedicineInstitute for Global Health Policy Research, Bureau of International Health Cooperation, National Center for Global Health and MedicineInstitute for Global Health Policy Research, Bureau of International Health Cooperation, National Center for Global Health and MedicineInstitute for Global Health Policy Research, Bureau of International Health Cooperation, National Center for Global Health and MedicineAbstract Coronavirus disease-2019 (COVID-19) is associated with a wide range of post-acute sequelae. The prevalence of erectile dysfunction (ED) that developed after COVID-19 and the associated underlying factors were analyzed based on a questionnaire survey, COVID-19 Recovery Study II in Japan. A case–control study was conducted with those with or without ED one and two years hospitalized with COVID-19 between March and September 2021. Six hundred and nine Japanese men, with a median age of 48 years, were analyzed. During the study period, 116 subjects (19.0%) had erectile dysfunction. The patients with ED responded with less subjective awareness of recovery and high breathless and fatigue scores compared to those without ED. The patients with ED also showed higher Hospital Anxiety and Depression Scale-D (depression) and the EuroQol 5-dimensions 5-level scores for pain/discomfort and anxiety/depression scores compared before COVID-19 infection. Sleep disturbance was suggested to be associated with erectile dysfunction using an exploratory clustering analysis in the one-year survey. There were no associations of COVID-19 severity, reinfection, vaccination frequency, antiviral treatment for COVID-19 with the presence of erectile dysfunction. It was considered that mental support for the subject with erectile dysfunction as a long-COVID symptom is warranted.https://doi.org/10.1038/s41598-025-88904-6Coronavirus disease-2019 (COVID-19)Erectile dysfunctionPost-acute sequelaeSleep disorderCOVID-19 Recovery Study II (CORES II)
spellingShingle Hideaki Kato
Nao Ichihara
Hiroki Saito
Shigeki Fujitani
Kohei Ota
Yuji Takahashi
Toshiyuki Harada
Takeshi Hattori
Mitsuru Komeya
Mariko Hosozawa
Yoko Muto
Miyuki Hori
Arisa Iba
Hiroyasu Iso
Hiroyasu Iso
The COVID-19 Recovery Study II Group
Prevalence of erectile dysfunction as long-COVID symptom in hospitalized Japanese patients
Scientific Reports
Coronavirus disease-2019 (COVID-19)
Erectile dysfunction
Post-acute sequelae
Sleep disorder
COVID-19 Recovery Study II (CORES II)
title Prevalence of erectile dysfunction as long-COVID symptom in hospitalized Japanese patients
title_full Prevalence of erectile dysfunction as long-COVID symptom in hospitalized Japanese patients
title_fullStr Prevalence of erectile dysfunction as long-COVID symptom in hospitalized Japanese patients
title_full_unstemmed Prevalence of erectile dysfunction as long-COVID symptom in hospitalized Japanese patients
title_short Prevalence of erectile dysfunction as long-COVID symptom in hospitalized Japanese patients
title_sort prevalence of erectile dysfunction as long covid symptom in hospitalized japanese patients
topic Coronavirus disease-2019 (COVID-19)
Erectile dysfunction
Post-acute sequelae
Sleep disorder
COVID-19 Recovery Study II (CORES II)
url https://doi.org/10.1038/s41598-025-88904-6
work_keys_str_mv AT hideakikato prevalenceoferectiledysfunctionaslongcovidsymptominhospitalizedjapanesepatients
AT naoichihara prevalenceoferectiledysfunctionaslongcovidsymptominhospitalizedjapanesepatients
AT hirokisaito prevalenceoferectiledysfunctionaslongcovidsymptominhospitalizedjapanesepatients
AT shigekifujitani prevalenceoferectiledysfunctionaslongcovidsymptominhospitalizedjapanesepatients
AT koheiota prevalenceoferectiledysfunctionaslongcovidsymptominhospitalizedjapanesepatients
AT yujitakahashi prevalenceoferectiledysfunctionaslongcovidsymptominhospitalizedjapanesepatients
AT toshiyukiharada prevalenceoferectiledysfunctionaslongcovidsymptominhospitalizedjapanesepatients
AT takeshihattori prevalenceoferectiledysfunctionaslongcovidsymptominhospitalizedjapanesepatients
AT mitsurukomeya prevalenceoferectiledysfunctionaslongcovidsymptominhospitalizedjapanesepatients
AT marikohosozawa prevalenceoferectiledysfunctionaslongcovidsymptominhospitalizedjapanesepatients
AT yokomuto prevalenceoferectiledysfunctionaslongcovidsymptominhospitalizedjapanesepatients
AT miyukihori prevalenceoferectiledysfunctionaslongcovidsymptominhospitalizedjapanesepatients
AT arisaiba prevalenceoferectiledysfunctionaslongcovidsymptominhospitalizedjapanesepatients
AT hiroyasuiso prevalenceoferectiledysfunctionaslongcovidsymptominhospitalizedjapanesepatients
AT hiroyasuiso prevalenceoferectiledysfunctionaslongcovidsymptominhospitalizedjapanesepatients
AT thecovid19recoverystudyiigroup prevalenceoferectiledysfunctionaslongcovidsymptominhospitalizedjapanesepatients